Showing results (131-140 of 170) with videos related to

Sort By:
Pageof 17
Cell Chemical Biology|October 24, 2017
Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7Ilaria Lamberto, Xiaoxi Liu, Hyuk-Soo Seo, et al.
Oncogene|June 9, 2005
Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathwayKenji Ishitsuka, Teru Hideshima, Makoto Hamasaki, et al.
Blood|April 9, 2004
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistanceDharminder Chauhan, Guilan Li, Klaus Podar, et al.
Blood|November 9, 2002
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsNicholas Mitsiades, Constantine S Mitsiades, Paul G Richardson, et al.
Cancer Cell|October 6, 2009
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic targetDharminder Chauhan, Ajita V Singh, Mohan Brahmandam, et al.
Blood|May 7, 2009
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myelomaMariateresa Fulciniti, Pierfrancesco Tassone, Teru Hideshima, et al.
Blood|January 11, 2023
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myelomaTing Du, Yan Song, Arghya Ray, et al.
Blood|May 19, 2007
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesisYu-Tzu Tai, Mariateresa Fulciniti, Teru Hideshima, et al.
British Journal of Haematology|September 1, 2007
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cellsTeru Hideshima, Laurence Catley, Noopur Raje, et al.
Blood|January 14, 2017
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myelomaTeru Hideshima, Francesca Cottini, Yoshihisa Nozawa, et al.
Pageof 17